

August 9, 2018



Pressure BioSciences, Inc. President and CEO, Richard T. Schumacher, Discusses Recent Company Achievements with Everett Jolly on Uptick Newswire's "Stock Day" Podcast

PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire today announced the release of an interview with Richard T. Schumacher, President and CEO of Pressure BioSciences, Inc. (OTCQB:PBIO) (the "Company") on Uptick Newswire's "Stock Day" Podcast. The interview was conducted by Uptick's President, Everett Jolly.

Mr. Jolly began the interview by welcoming Mr. Schumacher back on the program. Mr. Jolly stated that he was "super, super excited" about PBIO for numerous reasons. He stated it was his belief that Pressure BioSciences was about to create a paradigm shift in the dairy and beverage industries because of the Company's publicly announced plans to develop a novel processing method for milk and other liquid foods that could result in such products being stable for extended periods of time without requiring refrigeration or chemical preservatives.

Mr. Jolly asked Mr. Schumacher to give his new listeners some background information on Pressure BioSciences.

Mr. Schumacher stated that PBIO is a life sciences company with three unique and enabling technology platforms, all of which are patent protected and all of which are based on using an amazing force of Mother Nature – Pressure. Mr. Schumacher stated that pressure is very powerful because it moves at the speed of sound, yet it can still be turned on and off like a light switch. Mr. Schumacher added that all biological entities in the world (such as normal or cancer cells, bacteria, and viruses) have a pressure point at which they can be controlled. Thus, if you can exert different levels of pressure on a molecule in a laboratory or manufacturing process, you can control different biomolecules (like DNA and proteins) – such exquisite control of cells and molecules could then create a paradigm shift.

As a way to commercialize their pressure technology, the Company has developed a series of instruments, based on three pressure technology platforms, that can exquisitely and safely control pressure. In their first technology platform, called pressure cycling technology or PCT, they have 15 patents, about 300 instruments sold, and over 200 customers, including some of the top research scientists and laboratories in the nation and the world, particularly scientists who study the relationship of proteins to human, animal, and plant diseases and disorders. Many lab studies have been shown to be enhanced by pressure; such studies could result in the development of new drugs or therapies and could lead to new cures and disease preventive strategies. The Company reported \$2.2 million in the PCT

technology platform area last year and has given guidance they expect revenue to continue to increase in 2018 and beyond.

The second patented pressure platform came from a company they purchased in December 2017. Although they are still moving the equipment and materials they purchased from Colorado to Massachusetts, they're already seeing revenue from services that at least one large, multi-national company has hired them to perform. The acquisition included about eight patents, and several more that have been filed and are pending. This pressure platform technology is called PreEMT. It is a method that helps drug companies create and improve the quality of their protein drugs. There are over 200 protein drugs on the market today for all kinds of diseases and disorders, and there are dozens upon dozens of drug companies developing new protein-based drugs. The Company believes that these companies are all potential future customers, and this new service line can potentially add significantly to revenue in the coming quarters.

The third pressure-based, patented technology platform is called Ultra Sheer Technology, or UST. The Company has two patents already issued for UST and believe that they will be issued additional patents in the coming months and years. UST involves putting liquids (e.g., milk, plus other dairy products and liquid beverages) under pressure, then releasing the liquid material while still under pressure through a series of valves they have developed. This then shears (cuts) any oil, fat droplets, lipids, etc. that are part of the liquid beverage. Mr. Schumacher said, "So, if there are bacteria or viruses in the liquid food, the UST process will kill these pathogens, bringing their level down to what is known as manufacturing sterile. This will allow the beverage to sit at room temperature storage for extended periods of time (weeks to months), without the need for refrigeration or chemical preservatives."

Mr. Jolly said, "Let me see if I understand this as I want to be sure that my listeners will understand it, too. You believe that once your UST process has been developed, it has the potential to allow a food manufacturer to take liquid foods like milk and juice, process them with UST, and the final product will be free of pathogens and chemical preservatives, and will not require refrigerated transport and storage. Am I hearing you correct?"

"Yes, Everett, we believe that the UST process will do just that," responded Mr. Schumacher.

"WOW!" Mr. Jolly exclaimed.

Mr. Schumacher then emphasized that several things consumers now want is food that is preservative-free with long, room temperature shelf-life. He further emphasized that if you're able to reduce pathogens in food to commercially sterile levels, then you will not need to refrigerate the product afterwards or add chemical preservatives.

Mr. Schumacher continued, "There are liquid food products on the market today that are non-refrigerated. The problem is that most do not taste good at all! We believe that UST has the potential of delivering to consumers liquid food products that actually look and taste good while having a longer shelf life without preservatives or refrigeration. Additionally, UST processing offers potential applications that go well beyond food to include pharmaceuticals and nutraceuticals and other items such as lubricants, paints, and cosmetics."

Last month, Ohio State announced they will be collaborating with the Company in this new, paradigm-shifting, and potentially breakthrough area. The USDA awarded Ohio State an

\$891,000 grant of which Pressure BioSciences will be receiving about \$318,000 to work on this new method with a goal to bring UST to commercialization. The first phase of the collaboration, which has already begun, is to build a working prototype instrument. Mr. Schumacher believes that it's only a matter of months before they can begin putting all kinds of liquid foods and other material through this prototype machine. Because such processing is so new and cutting-edge, the data should be very, very interesting to the Company.

Mr. Jolly concluded by asking if there was anything further his guest wanted to convey.

Mr. Schumacher commented that although the Company has been achieving success after success over the past year or two, the PBIO stock volume and price have not yet responded, and thus he believed the value of the Company was not fairly shown in the stock.

Mr. Jolly emphatically agreed and stated again he believed that PBIO is highly undervalued.

For more information about Pressure BioSciences, you can listen to the full interview at the link below:

<https://upticknewswire.com/featured-interview-ceo-ric-schumacher-of-pressure-biosciences-inc-otcqb-pbio-7/>

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. Our products are based on the unique properties of both constant (*i.e.*, static) and alternating (*i.e.*, pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil and plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of our pressure-based technologies in the following areas: (1) the use of our recently acquired PreEMT technology from BaroFold, Inc., to allow entry into the biologics contract research services sector, and (2) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") platform (i) to create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and (ii) to prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.

Contact:

Pressure BioSciences, Inc.
Corporate Office
14 Norfolk Avenue
South Easton, MA 02375
(508) 230-1828

<http://www.pressurebiosciences.com/>
info@pressurebiosciences.com

Safe Harbor Act and Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors are contained in the Company’s most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

About Uptick Newswire and the “Stock Day” Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its “Stock Day” Podcast, which is the number one radio show of its kind in America. The Uptick Network “Stock Day” Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of “Stock Day,” and Uptick Newswire encourages listeners to visit the company’s message board at <https://investorshangout.com/>

Source: Pressure BioSciences, Inc.